Buy & Sell Open Text Corporation (OTEX) – Open Text Corporation Price Today
Aura AI Summary
Key Stats
- $5.53BMarket Cap
- TechnologySector
- -20.34%3M Drawdown
- $10.69BEnterprise Value
- 4.82%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 6 daysTypical Hold Time
Open Text Corporation (OTEX) is currently valued at a market capitalization of $5.53B, with an enterprise value of $10.69B. Over the past 52 weeks, Open Text Corporation has traded between a low of $20.56 and a high of $39.69, highlighting its annual price range. Over the past three months, Open Text Corporation has recorded a drawdown of -20.34%, reflecting recent price volatility. Open Text Corporation offers a dividend yield of 4.82%. On average, investors hold Open Text Corporation for approximately 6 days, indicating typical investor behavior on the platform.
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Most Recent News
Class action deadlines near for investors in ATRA, COTY, SMCI, and IBRX over alleged securities fraud.
Law Offices of Howard G. Smith reminds investors of approaching deadlines to file lead plaintiff motions in securities fraud class actions against Atara Biotherapeutics, Coty Inc., Super Micro Computer, and ImmunityBio. The lawsuits allege these comp...
Meta's Q1 beat fueled by tax benefit, while Microsoft shows stronger AI revenue and cash returns.
Meta Platforms reported a strong Q1 with EPS of $10.44 beating expectations, but much of the beat was due to an $8.03 billion tax benefit, masking weaker core performance and rising capital expenditures. Meta's AI and Reality Labs investments are cos...
Phreesia faces class action over lowered 2027 revenue outlook and weakened pharma marketing commitments.
Phreesia, a healthcare SaaS company, is facing a class action lawsuit from investors who bought its stock between May 2025 and March 2026. The lawsuit alleges Phreesia misled investors by not disclosing weakening pharmaceutical marketing commitments ...